Abstract

Proteomic studies of human Alzheimer’s disease brain tissue have potential to identify protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 published Alzheimer’s disease proteomic studies, generating a map of protein changes in human brain tissue across thirteen brain regions, three disease stages (preclinical Alzheimer’s disease, mild cognitive impairment, advanced Alzheimer’s disease), and proteins enriched in amyloid plaques, neurofibrillary tangles, and cerebral amyloid angiopathy. Our dataset is compiled into a searchable database (NeuroPro). We found 848 proteins were consistently altered in 5 or more studies. Comparison of protein changes in early-stage and advanced Alzheimer’s disease revealed proteins associated with synapse, vesicle, and lysosomal pathways show change early in disease, but widespread changes in mitochondrial associated protein expression change are only seen in advanced Alzheimer’s disease. Protein changes were similar for brain regions considered vulnerable and regions considered resistant. This resource provides insight into Alzheimer’s disease brain protein changes and highlights proteins of interest for further study.

Proteomic studies in Alzheimer’s disease may be useful for understanding disease mechanisms and potential therapeutic targets. Here the authors describe a resource collating known protein changes throughout the progression of Alzheimer’s disease in human brain tissue.

Details

Title
Compilation of reported protein changes in the brain in Alzheimer’s disease
Author
Askenazi, Manor 1   VIAFID ORCID Logo  ; Kavanagh, Tomas 2 ; Pires, Geoffrey 3 ; Ueberheide, Beatrix 4 ; Wisniewski, Thomas 3   VIAFID ORCID Logo  ; Drummond, Eleanor 5   VIAFID ORCID Logo 

 Biomedical Hosting LLC, Arlington, USA 
 University of Sydney, Brain and Mind Centre and School of Medical Sciences, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X) 
 New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
 New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University, Proteomics Laboratory, Division of Advanced Research Technologies, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University, Biochemistry and Molecular Pharmacology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
 University of Sydney, Brain and Mind Centre and School of Medical Sciences, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); New York University, Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
Pages
4466
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2841686817
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.